OR WAIT 15 SECS
September 14, 2016
Although the ophthalmology market has experienced relatively little advancement in recent years, with large unmet needs remaining there are strong opportunities for more products to enter the treatment space, according to a report by GBI Research.
Scientific advancements, such as glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome, have revealed a broad range of novel potential molecular targets in recent decades. This is reflected, states the report, by the high number of products in development, with 782 products currently in the ophthalmology therapy pipeline. Current first-in-class approaches to treatment, such as topical nerve growth factor application and slowing of the visual cycle, have being gaining significant traction in preclinical and clinical trials. With such promise in the pipeline, the ophthalmology deals landscape is highly active, says the report. Frontier Pharma: Ophthalmology Therapeutics.